Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
GH Secretagogue (GHRP)

GHRP-2 — Growth Hormone Releasing Peptide 2 (Research Evidence Summary)

Research evidence summary

also known as KP-102, Pralmorelin, Growth Hormone Releasing Peptide 2

GHRP-2 (pralmorelin) is a synthetic ghrelin-receptor agonist. Human studies range from one-off diagnostic tests to trials in children, and long-term safety is not established.

Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (hexapeptide)
MW
817.9 Da
Receptor
GHSR-1a (ghrelin receptor)
Half-life
0.55 hours (about 33 minutes) after a single intravenous dose in children; no adult or subcutaneous figure found PubMed 9543135
Quoted from the source
GHRP-2 PK parameters (mean +/- SD) were: alpha = 13.4 +/- 9.7 h(-1), beta = 1.3 +/- 0.3 h(-1), t(1/2beta) = 0.55 +/- 0.14 h,
Routes in study
IV (diagnostic tests), SC, Oral (children), Intranasal
Save

GHRP-2 (also known as pralmorelin or KP-102) is a synthetic hexapeptide agonist at the ghrelin receptor, GHSR-1a (see our GHSR-1a glossary entry). A 2004 drug profile says it comes from a series of compounds developed by Polygen in Germany and Tulane University, where a group led by Cyril Bowers synthesised small, highly active peptides (PMID 15230633).

How does it work?

An animal pharmacology study describes GHRP-2 as promoting growth hormone (GH) release by acting at both hypothalamic and pituitary sites (PMID 15646371). A human study describes it as a synthetic agonist of ghrelin, the gut peptide that binds the same receptor and stimulates both GH secretion and appetite (PMID 15699539). Its action differs from GHRH analogues such as CJC-1295 and tesamorelin, which act at the GHRH receptor. Synergy between a growth hormone-releasing peptide and GHRH was first reported with an earlier GHRP in 18 normal men (PMID 2108187); GHRP-2 given with GHRH(1-44) showed acute synergy 3-fold greater in 16 young volunteers than in 17 older ones (PMID 15126555). A PubMed search for GHRP-2 AND CJC-1295 on 6 November 2026 returned 3 records (two 2026 reviews and an equine doping-analysis paper), none a human study of the pair.

It is cleared quickly. After a single 1 µg/kg intravenous dose in 10 prepubertal children of short stature, the terminal half-life was 0.55 hours, about 33 minutes (PMID 9543135). No adult or subcutaneous half-life was found.

What has been studied in people

The studies below come from PubMed on 2 November 2026, searching ("GHRP-2"[tiab] OR "GHRP 2"[tiab] OR "pralmorelin"[tiab] OR "KP-102"[tiab] OR "growth hormone-releasing peptide-2"[tiab] OR "growth hormone releasing peptide 2"[tiab]), which returned 238 records (the same count on 6 November 2026). Adding AND (clinical trial[pt] OR clinical study[pt] OR case reports[pt] OR humans[mh]) leaves 149; two studies in the table (PMID 25374440 and PMID 26401470) carry none of those tags. ClinicalTrials.gov, GHRP-2 OR pralmorelin OR KP-102, 6 November 2026: 0 records.

StudyDose and routeWho
Chihara 2007 (PMID 17609397)100 µg intravenously, single dose, blood sampled for 2 hours77 healthy adults and 58 adults with GH deficiency
Asakura 2010 (PMID 20662346)2 µg/kg intravenously, single dose56 children evaluated for GH deficiency
Arvat 1997 (PMID 9285939)1 and 2 µg/kg intravenously6 young adults; 2 µg/kg also in 6 elderly adults
Pihoker 1998 (PMID 9543135)1 µg/kg intravenously over 1 minute10 prepubertal children of short stature
Nijland 1998 (PMID 9820615)100 µg subcutaneously once daily for 5 days9 healthy subjects, single group
Van den Berghe 1999 (PMID 10199772)1 µg/kg/h infused with TRH (thyrotropin-releasing hormone) for 5 days, against placebo14 patients with protracted critical illness, crossover
Van den Berghe 2002 (PMID 12030918)1 µg/kg/h infused for 5 days, alone or with TRH and GnRH (gonadotropin-releasing hormone), against placebo33 men with prolonged critical illness, randomised
Bowers 1996 (PMID 8887169)Chronic administration for 7 to 30 days; dose and route not given in the abstractNormal younger and older men and women
Bowers 2001 (PMID 11322505)1 µg/kg/h by continuous subcutaneous infusion for 30 daysAdults with decreased GH secretion
Bowers 2004 (PMID 15126555)1 µg/kg/h by continuous subcutaneous infusion for 30 days17 healthy older men and women
Mericq 1998 (PMID 9661608)0.3, 1.0 and 3.0 µg/kg/day subcutaneously in successive 2-month periods6 prepubertal children with GH deficiency
Mericq 2003 (PMID 14513874)900 µg/kg orally twice daily for 12 months10 prepubertal children with GH deficiency
Pihoker 1997 (PMID 9390009)5 to 15 µg/kg intranasally twice a day for 3 months, then three times a day15 children with short stature; 6 followed for 18 to 24 months
Tanaka 2014 (PMID 25374440)Intranasal spray, 50 to 200 µg twice daily by body weight, for 48 weeks126 prepubertal short children with GH deficiency, double-blind
Haruta 2015 (PMID 26401470)Intranasal, before every meal, for 1 yearOne patient with anorexia nervosa (case report)
Sigalos 2017 (PMID 28830317)100 mcg each of GHRP-6, GHRP-2 and sermorelin, three times daily; route not stated in the abstractChart review of 105 men on testosterone therapy; 14 analysed, mean 134 days of treatment

What these studies found:

  • Diagnostic use. A 100 µg intravenous dose raised peak GH to 84.6 µg/L in healthy adults against 1.36 µg/L in patients with GH deficiency; a cut-off of 15 µg/L corresponded to the diagnostic value of 3 µg/L in the insulin tolerance test (PMID 17609397). This is a one-off test dose, not a treatment dose.
  • Repeated injections. In nine healthy subjects given 100 µg subcutaneously daily for 5 days, with no comparison group described, peak GH fell from 83 to 59 to 51 µg/L on days 1, 3 and 5 (response attenuation, P < 0.01) and mean serum IGF-I (insulin-like growth factor I) did not rise (PMID 9820615). Bowers 1996 says whether the GH response becomes desensitised during chronic administration "depends in part on the dosage and frequency of administration" (PMID 8887169).
  • Critical illness. In placebo-controlled trials, 5-day infusions reactivated GH secretion and raised IGF-I (PMID 10199772; PMID 12030918). Osteocalcin rose with GHRP-2 plus TRH (19% against -6% on placebo; PMID 10199772) and, in the second trial, with GHRP-2 plus TRH and GnRH (P = 0.03; a trend with GHRP-2 plus TRH, P = 0.09) but not with GHRP-2 alone (PMID 12030918). See Safety and unknowns for other findings in these trials.
  • Continuous infusion. In adults with decreased GH secretion, 30 days of infusion raised pulsatile GH and serum IGF-1 after 24 hours, and IGF-1 stayed elevated for 30 days (PMID 11322505). This was pump delivery in a research setting.
  • Children. Subcutaneous doses of 0.3 to 3.0 µg/kg/day in 2-month steps did not raise IGF-I or IGFBP-3 (an IGF-binding protein) (PMID 9661608). Seven of ten children on the oral dose reported a significant increase in appetite in the first 6 months (PMID 14513874). In the 48-week intranasal trial, mean height SD score (a measure of growth against the average for age) changed by 0.07 on placebo, 0.03 on the lower dose and 0.02 on the higher dose, with no significant differences and no change in IGF-I; the authors concluded that a transient rise in endogenous GH does not promote growth (PMID 25374440). In the earlier report with no placebo group described, height velocity rose from 3.7 to 6.1 cm/year and IGF-1 did not change significantly (PMID 9390009).
  • Chart review and case report. In the three-peptide chart review the effect of GHRP-2 cannot be separated; mean IGF-1 in the 14 men analysed rose from 159.5 to 239.0 ng/mL (PMID 28830317). In one patient with anorexia nervosa, intranasal GHRP-2 for 1 year was followed by a rise in body weight from 21.1 kg to 27.8 kg over 14 months, with no obvious side effects reported (PMID 26401470).

Use in Japan

The abstract of the case report above says: "In Japan, growth hormone releasing peptide-2 (GHRP-2) is clinically used as a diagnostic agent for growth hormone secretion deficiency" (PMID 26401470). A 2013 Japanese comparison study states that "the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan" for diagnosing adult GH deficiency (PMID 23079545). A 2004 drug profile reported pralmorelin (KP-102 D) as awaiting approval in Japan as a diagnostic agent and said US development for GH deficiency appeared to have been discontinued (PMID 15230633). No Japanese approval document was found.

Safety and unknowns

  • FDA. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists "Growth hormone releasing peptide-2 (GHRP-2) (for injectable and nasal routes of administration)" in category 2 under the 503B interim policy, added 29 September 2023. Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry reads: "Compounded drugs containing GHRP-2 for injectable and nasal administration may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. GHRP-2 also contains an unnatural amino acid, which adds to the complexity of peptide characterization. FDA is aware of reports of serious adverse advents [sic] in patients who received GHRP-2, including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis, though causality has not been established." FDA's entry links to the 1999 five-day critical-illness infusion trial described above (PMID 10199772), whose abstract does not mention deaths.
  • Other hormones. In six young adults, intravenous GHRP-2 and hexarelin were not fully specific for GH: they induced similar increases in prolactin, ACTH (adrenocorticotropic hormone) and cortisol, and the ACTH and cortisol response was similar to that to hCRH, a hormone that stimulates the adrenal axis (PMID 9285939). In critically ill patients, cortisol was not detectably altered by 5 days of GHRP-2 plus TRH (PMID 10199772); in the second trial, serum lactate and white blood cell counts were higher on day 5 after GHRP-2 infused alone and with TRH, but not with TRH and GnRH (PMID 12030918).
  • Appetite. GHRP-2 increased food intake in healthy men (PMID 15699539) and appetite in children on oral dosing (PMID 14513874). A 2026 review's table for GHRP-2 lists increased appetite and prolactin changes in short-term studies and no long-term safety data (PMID 42395176).
  • Duration. In adults, injection or infusion studies lasted 5 to 30 days; the longest exposures were a one-year intranasal case report and, in children, up to 2 years (6 children, intranasal).
  • Long-term safety. A 2018 review of GH secretagogues concluded that long-term safety, including cancer incidence and mortality, still needs to be studied; it noted some concern for rises in blood glucose because of decreases in insulin sensitivity (PMID 28400207).

Anti-doping

The World Anti-Doping Agency 2026 Prohibited List names GHRP-2 (pralmorelin) among the growth hormone releasing factors under S2.2.4, prohibited at all times. Methods for detecting GHRP metabolites in urine after nasal administration have been published (PMID 25869809). See peptides and sports anti-doping.

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Common online claims vs evidence

  • Claim: "GHRP-2 is the strongest GH secretagogue." Reality: in conscious swine GHRP-2 showed higher potency but lower efficacy than ipamorelin (PMID 9849822); no human comparison was found (PubMed, ipamorelin AND (GHRP-2 OR pralmorelin), 3 November 2026: 19 records).
  • Claim: "GHRP-2 builds muscle without raising IGF-1." Reality: IGF-1 findings depend on the route. Five days of daily subcutaneous injection did not raise mean IGF-I (PMID 9820615), while infusions did (PMID 11322505; PMID 12030918). Muscle outcomes appear only in a single uncontrolled report of one patient with anorexia nervosa, which describes improved fatigability and muscle strength (PMID 26401470).

Regulatory and clinical status

UK status: No US label found: a DailyMed name search on 6 November 2026 returned none. A 2013 Japanese study says a GHRP-2 test is recommended in Japan as an alternative for diagnosing adult GH deficiency, and a 2004 drug profile reported pralmorelin awaiting approval there as a diagnostic agent. No Japanese approval document was found. FDA safety statement: see Safety and unknowns. Named under S2.2.4 of the WADA 2026 Prohibited List.

Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Furuta S, Shimada O, Doi N, et al.. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12) :868-80 doi:10.1055/s-0031-1297042 · PMID: 15646371
  2. n/a. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R&D. 2004;5(4) :236-239 doi:10.2165/00126839-200405040-00011 · PMID: 15230633
  3. Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5) :552-61 doi:10.1530/eje.0.1390552 · PMID: 9849822
  4. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 1990;70(4) :975-82 doi:10.1210/jcem-70-4-975 · PMID: 2108187
  5. Chihara K, Shimatsu A, Hizuka N, et al.. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European Journal of Endocrinology. 2007;157(1) :19-27 doi:10.1530/EJE-07-0066 · PMID: 17609397
  6. Asakura Y, Toyota Y, Muroya K, Adachi M. Growth hormone response to GH-releasing peptide-2 in children. Journal of pediatric endocrinology & metabolism : JPEM. 2010;23(5) :473-80 doi:10.1515/jpem.2010.078 · PMID: 20662346
  7. Kinoshita Y, Tominaga A, Usui S, et al.. The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison. Endocrine Journal. 2013;60(1) :97-105 doi:10.1507/endocrj.ej12-0230 · PMID: 23079545
  8. Arvat E, di Vito L, Maccagno B, et al.. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6) :885-91 doi:10.1016/s0196-9781(97)00016-8 · PMID: 9285939
  9. Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. Journal of Clinical Endocrinology and Metabolism. 1998;83(4) :1168-72 doi:10.1210/jcem.83.4.4744 · PMID: 9543135
  10. Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. European Journal of Endocrinology. 1998;139(4) :395-401 doi:10.1530/eje.0.1390395 · PMID: 9820615
  11. Bowers CY, Granda-Ayala R. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. 2001;14(1) :79-86 doi:10.1385/ENDO:14:1:079 · PMID: 11322505
  12. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. Journal of Clinical Endocrinology and Metabolism. 2004;89(5) :2290-300 doi:10.1210/jc.2003-031799 · PMID: 15126555
  13. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology and Metabolism. 2005;90(2) :611-4 doi:10.1210/jc.2004-1719 · PMID: 15699539
  14. Mericq V, Cassorla F, Salazar T, et al.. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology and Metabolism. 1998;83(7) :2355-60 doi:10.1210/jcem.83.7.4969 · PMID: 9661608
  15. Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. Journal of pediatric endocrinology & metabolism : JPEM. 2003;16(7) :981-5 doi:10.1515/jpem.2003.16.7.981 · PMID: 14513874
  16. Pihoker C, Badger TM, Reynolds GA, Bowers CY. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. Journal of Endocrinology. 1997;155(1) :79-86 doi:10.1677/joe.0.1550079 · PMID: 9390009
  17. Tanaka T, Hasegawa Y, Yokoya S, Nishi Y. Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency. Clinical Pediatric Endocrinology. 2014;23(4) :107-14 doi:10.1297/cpe.23.107 · PMID: 25374440
  18. Sigalos JT, Pastuszak AW, Allison A, et al.. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American Journal of Men's Health. 2017;11(6) :1752-1757 doi:10.1177/1557988317718662 · PMID: 28830317
  19. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1) :45-53 doi:10.1016/j.sxmr.2017.02.004 · PMID: 28400207
  20. Semenistaya E, Zvereva I, et al.. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Testing and Analysis. 2015;7(10) :919-925 doi:10.1002/dta.1787 · PMID: 25869809
  21. Haruta I, Fuku Y, Kinoshita K, et al.. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. Journal of Cachexia, Sarcopenia and Muscle. 2015;6(3) :237-41 doi:10.1002/jcsm.12028 · PMID: 26401470
  22. Dominikowski A, et al.. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology. 2026 doi:10.3389/fendo.2026.1822475 · PMID: 42395176
  23. Van den Berghe G, Wouters P, Weekers F, et al.. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. Journal of Clinical Endocrinology and Metabolism. 1999;84(4) :1311-23 doi:10.1210/jcem.84.4.5636 · PMID: 10199772
  24. Van den Berghe G, Baxter RC, Weekers F, et al.. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical Endocrinology. 2002;56(5) :655-69 doi:10.1046/j.1365-2265.2002.01255.x · PMID: 12030918
  25. Bowers CY, Granda-Ayala R. GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. Journal of pediatric endocrinology & metabolism : JPEM. 1996;9(Suppl 3) :261-70 · PMID: 8887169
Published: 2026-07-09Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the sequence given was GHRP-6's and an unsourced half-life was removed; 'approved in Japan' was re-attributed to the papers saying it; human studies and FDA's safety statement were added; legal text was replaced.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading